7月31日，德康医疗盘后上涨6.28%，报78.07美元/股，成交额2080.01万美元。
消息面上，公司发布第二季度财报，业绩全面超出市场预期。Q2调整后每股收益0.70美元，大幅超越分析师一致预期的0.61美元，同比增长45.83%；营收13.08亿美元，超预期的12.90亿美元，同比增长约12.9%。同时公司上调全年营收指引至51.8亿至52.5亿美元，此前区间下限为51.6亿美元。
基本面来看，公司CGM设备需求持续强劲，G7系统近期获加拿大卫生部15天版本授权，德国市场推出Flex系统拓展2型糖尿病覆盖，叠加Medicare全国覆盖决定催化预期，多家投行维持买入评级，平均目标价约86美元。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.